Results
|
1.
|
|
|
2.
|
|
|
3.
|
|
|
4.
|
|
|
5.
|
|
|
6.
|
|
|
7.
|
|
|
8.
|
Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial. [electronic resource] by
- Ferrari, Michel D
- Diener, Hans Christoph
- Ning, Xiaoping
- Galic, Maja
- Cohen, Joshua M
- Yang, Ronghua
- Mueller, Matthias
- Ahn, Andrew H
- Schwartz, Yael Carmeli
- Grozinski-Wolff, Melissa
- Janka, Lindsay
- Ashina, Messoud
Producer: 20191017
In:
Lancet (London, England) vol. 394
Availability: No items available.
|